Cosentyx

FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
Yahoo Finance
Novartis
Cosentyx
FDA
hidrad
Flag link:
Novartis Wins FDA Approval for Intravenous Cosentyx Formulation
Novartis Wins FDA Approval for Intravenous Cosentyx Formulation
BioSpace
Novartis
Cosentyx
FDA
ankylosing spondylitis
psoriatic arthritis
non-radiographic axial spondyloarthritis
Flag link:
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
Fierce Pharma
Novartis
Cosentyx
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
Flag link:
Novartis touts Cosentyx win in debilitating skin condition. Can it challenge AbbVie's Humira?
Novartis touts Cosentyx win in debilitating skin condition. Can it challenge AbbVie's Humira?
Fierce Pharma
Novartis
FDA
Cosentyx
AbbVie
Humira
hidradenitis suppurativa
Flag link:
FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents
FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents
Pharmaceutical Business Review
Novartis
FDA
Cosentyx
arthritis
pediatric
Flag link:
The top 15 blockbuster patent expirations coming this decade
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
patents
patent cliff
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Revlimid
Pfizer
Eliquis
Regeneron
Eylea
JNJ
Stelara
Opdivo
GSK
Dolutegravir
Ibrance
Januvia
Eli Lilly
Trulicity
Novo Nordisk
Victoza
Amgen
Prolia
Xgeva
Novartis
Cosentyx
Takeda
Entyvio
Flag link:
Novartis stakes another PhIII win for Cosentyx, goes deeper into pediatric markets
Novartis stakes another PhIII win for Cosentyx, goes deeper into pediatric markets
Endpoints
Novartis
Cosentyx
juvenile idiopathic arthritis
Flag link:
Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis podcast
Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis podcast
Fierce Pharma
Novartis
podcasts
psoriasis
celebrity endorsements
Cosentyx
Flag link:
UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market
UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market
Endpoints
UCB Pharma
psoriasis
bimekizumab
Cosentyx
Flag link:
Eli Lilly’s Mirikizumab Hits the Mark in Phase III Study, Bests Cosentyx
Eli Lilly’s Mirikizumab Hits the Mark in Phase III Study, Bests Cosentyx
BioSpace
Eli Lilly
psoriasis
mirikizumab
clinical trials
Cosentyx
Novartis
Flag link:
Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis
Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis
Pharmaceutical Business Review
Novartis
Cosentyx
non-radiographic axial spondyloarthritis
Flag link:
Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis
Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis
Fierce Pharma
Novartis
Eli Lilly
Cosentyx
Taltz
spondyloarthritis
Flag link:
UCB’s growth driver squares up against the competition
UCB’s growth driver squares up against the competition
EP Vantage
UCB Pharma
bimekizumab
psoriasis
clinical trials
Novartis
Cosentyx
Flag link:
Eli Lilly's Taltz beats Novartis to the punch with FDA approval in spondyloarthritis
Eli Lilly's Taltz beats Novartis to the punch with FDA approval in spondyloarthritis
Fierce Pharma
Eli Lilly
Taltz
Novartis
Cosentyx
axial spondyloarthritis
Flag link:
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
Motley Fool
AbbVie
Boehringer Ingelheim
Skyrizi
Novartis
Cosentyx
psoriasis
Flag link:
Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial
Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial
BioSpace
Novartis
Cosentyx
AbbVie
Humira
clinical trial
psoriatic arthritis
Flag link:
Novartis stacks more positive PhIII data on Cosentyx franchise — eyeing approval in non-radiographic axial spondyloarthritis
Novartis stacks more positive PhIII data on Cosentyx franchise — eyeing approval in non-radiographic axial spondyloarthritis
Endpoints
Novartis
Cosentyx
axial spondyloarthritis
Flag link:
Novartis’ Cosentyx heads for fourth indication after supportive data in early ankylosing spondylitis
Novartis’ Cosentyx heads for fourth indication after supportive data in early ankylosing spondylitis
Pharmaforum
Novartis
Cosentyx
ankylosing spondylitis
Flag link:
Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study
Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study
Pharmaceutical Business Review
Novartis
Cosentyx
clinical trials
psoriatic arthritis
Flag link:
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Pharmaceutical Business Review
Novartis
Cosentyx
China
psoriasis
Flag link:

Pages